2017年最新溃疡性结肠炎治疗指南

Ulcerative colitis (UC) is a chronic inflammatory bowel disease haracterized by a relapsing and remitting course. The direct and indirect costs of the treatment of UC are high, and the quality of life of patients is reduced, especially during exacerbation of the disease. The incidence and prevalence of UC in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Various medical and surgical therapies, including biologics, are currently used for the management of UC. However, many challenging issues exist, which sometimes lead to differences in practice between clinicians. Therefore, the IBD study group of the Korean Association for the Study of Intestinal Diseases established the first Korean guidelines for the management of UC in 2012. This is an update of the first guidelines. It was generally made by the adaptation of several foreign guidelines as was the first edition, and encompasses treatment of active colitis, maintenance of remission,and indication of surgery for UC. The specific recommendations are presented with the quality of evidence and classification of recommendations.

1. 临床评分量表：
   

2. 5-ASA的给药方式：

3. 轻中度UC的治疗—直肠炎，proctitis：

4. 轻中度UC的治疗—左侧结肠和广泛性结肠炎：

5. 激素难治性轻中度UC的治疗：

6. 中重度UC治疗—常规和激素治疗：

7. 激素难治性中重度UC的治疗：

8. 中重度UCAnti-TNF治疗：

9. 其他生物制剂的治疗：

10. 5-ASA治疗：

11. 别嘌呤醇治疗：

12. 生物制剂治疗：

13. 手术治疗：